Celgene grants Antengene rights to TORC12 inhibitor for cancer

Celgene grants Antengene rights to TORC1/2 inhibitor for cancer

14:40 EST 3 Jan 2019 | Elsevier Business Intelligence

Celgene Corp. granted Antengene Corp. rights to develop and sell CC223 (renamed ATG008) in multiple Asian countries, includin...

Original Article: Celgene grants Antengene rights to TORC1/2 inhibitor for cancer

More From BioPortfolio on "Celgene grants Antengene rights to TORC1/2 inhibitor for cancer"